Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations.

Flotho C, Kratz CP, Bergsträsser E, Hasle H, Starý J, Trebo M, van den Heuvel-Eibrink MM, Wójcik D, Zecca M, Locatelli F, Niemeyer CM; European Working Group of Myelodysplastic Syndromes in Childhood.

Blood. 2008 Jan 15;111(2):966-7; author reply 967-8. doi: 10.1182/blood-2007-09-111831. No abstract available.

2.

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

Archambeault S, Flores NJ, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RP, Niemeyer CM, Bader P, Loh ML.

Blood. 2008 Feb 1;111(3):1124-7. Epub 2007 Nov 13.

3.

Hematopoietic cytokine receptor signaling.

Baker SJ, Rane SG, Reddy EP.

Oncogene. 2007 Oct 15;26(47):6724-37. Review.

PMID:
17934481
4.
5.

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

Flotho C, Kratz C, Niemeyer CM.

Curr Drug Targets. 2007 Jun;8(6):715-25. Review.

PMID:
17584027
6.

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW.

Blood. 2007 Aug 15;110(4):1092-7. Epub 2007 May 8.

7.

Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

Matsuda K, Shimada A, Yoshida N, Ogawa A, Watanabe A, Yajima S, Iizuka S, Koike K, Yanai F, Kawasaki K, Yanagimachi M, Kikuchi A, Ohtsuka Y, Hidaka E, Yamauchi K, Tanaka M, Yanagisawa R, Nakazawa Y, Shiohara M, Manabe A, Kojima S, Koike K.

Blood. 2007 Jun 15;109(12):5477-80. Epub 2007 Mar 1.

8.

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, Luo H, Hennighausen L, Tomasson MH.

Blood. 2007 May 1;109(9):3906-14. Epub 2007 Jan 11.

9.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

10.

JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia.

Zecca M, Bergamaschi G, Kratz C, Bergsträsser E, Danesino C, De Filippi P, Hasle H, Lisini D, Locatelli F, Pession A, Sainati L, Starý J, Trebo M, van den Heuvel-Eibrink M, Wójcik D, Niemeyer CM.

Leukemia. 2007 Feb;21(2):367-9. Epub 2006 Dec 7. No abstract available.

PMID:
17151700
11.

Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA.

Blood. 2007 Feb 15;109(4):1687-91. Epub 2006 Nov 7.

12.
13.

Mapping normal and cancer cell signalling networks: towards single-cell proteomics.

Irish JM, Kotecha N, Nolan GP.

Nat Rev Cancer. 2006 Feb;6(2):146-55. Review.

PMID:
16491074
14.

Germline KRAS mutations cause Noonan syndrome.

Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP.

Nat Genet. 2006 Mar;38(3):331-6. Epub 2006 Feb 12. Erratum in: Nat Genet. 2006 May;38(5):598.

PMID:
16474405
15.

Implications of NRAS mutations in AML: a study of 2502 patients.

Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S.

Blood. 2006 May 15;107(10):3847-53. Epub 2006 Jan 24.

16.

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW.

Blood. 2005 Nov 15;106(10):3377-9. Epub 2005 Aug 4.

17.

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML.

Blood. 2005 Sep 15;106(6):2183-5. Epub 2005 May 31.

18.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A.

Blood. 2005 Aug 15;106(4):1207-9. Epub 2005 Apr 28.

19.

Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, Lee CM, Wulfert M, Germing U, Haas P, Niemeyer C, Beran ME, Strom S, Lübbert M, Sorcini M, Estey EH, Gattermann N, Tartaglia M.

Leuk Res. 2005 Apr;29(4):459-62. Epub 2004 Dec 30.

PMID:
15725481
20.

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, Akashi K, Gilliland DG, Neel BG.

Cancer Cell. 2005 Feb;7(2):179-91.

Supplemental Content

Support Center